Predicting tuberculosis relapse based on 28-day CFU, RS ratio, and/or drug contribution for novel regimens in the relapsing mouse model
van Wijk, R. C.; Solans, B. P.; Chaba, L.; Sordello, S.; Upton, A. M.; Nuermberger, E. L.; Robertson, G. T.; Walter, N. D.; Savic, R. M.
Show abstract
Treatment shortening in tuberculosis therapy is needed, but testing all novel antibiotic combinations is unfeasible. Especially the tuberculosis relapsing mouse model is time- and resource demanding. Therefore, our objective is to develop a computational model predictive of long-term relapse prevention in mice based on short-term biomarkers, increasing the number of regimens that can be tested and prioritize regimens for further development. The innovative ribosomal RNA synthesis (RS) ratio is utilized to characterize drug effect on Mycobacterium tuberculosis health and activity, together with colony forming units (CFU) in murine lungs. Nine datasets of 58 unique regimens with 843 short-term biomarker and 2,239 long-term relapse observations were leveraged for model development in 3 iterations with external validations. The final model included therapeutic predictors, such as CFU and RS ratio change from baseline, and corrected for experimental conditions, to enable unbiased ranking of regimens between experiments. Model performance was optimal without model structure change despite fully separate model development at each iteration. Final external validation had an area under the receiver operator curve of 0.90. Challenging the model by assessing removal of either biomarker showed that performance of CFU only was similar to CFU and RS ratio once the sterilizing contribution of individual drugs to the regimens was accounted for. New drugs without this contribution quantified could benefit from RS ratio determination to predict relapse. Our predictive model can successfully differentiate between 2-, 3-, and 4-month regimens in the relapsing mouse model based on 4-week data only, supporting acceleration of treatment-shortening regimen development. One Sentence SummaryOur predictive model ranks new drug regimens by tuberculosis relapse prevention based on 28-day CFU and RS ratio, or on CFU only for known drugs.
Matching journals
The top 1 journal accounts for 50% of the predicted probability mass.
Similar papers in this journal
- Model-Based Meta-Analysis of Relapsing Mouse Model Studies from the Critical Path to Tuberculosis Drug Regimens Initiative Database 98%
- Combination of Mycobacterium tuberculosis RS ratio and CFU improves the ability of murine efficacy experiments to distinguish between drug treatments 95%
- Using dynamic oral dosing of rifapentine and rifabutin to simulate exposure profiles of long-acting formulations in a mouse model of tuberculosis preventive therapy 95%
Similar papers in this journal
- Pre-clinical evaluation of antiviral activity of nitazoxanide against Sars-CoV-2 92%
- Ex vivo susceptibility to antimalarial drugs and polymorphisms in drug resistance genes of African Plasmodium falciparum , 2016-2023: a genotype-phenotype association study 91%
- Diagnostic accuracy of swab-based molecular tests for tuberculosis using novel near point-of-care platforms: A multi-country evaluation 90%
Similar papers in this journal
- Adherence trajectory as an on-treatment risk indicator among drug-resistant TB patients in the Philippines 93%
- A Bayesian approach to estimate the probability of resistance to bedaquiline in the presence of a genomic variant 92%
- Pharmacometabolomics in TB Meningitis – understanding the pharmacokinetic, metabolic, and immune factors associated with anti-TB drug concentrations in cerebrospinal fluid 92%
Similar papers in this journal
- A recombinant selective drug-resistant M. bovis BCG enhances the bactericidal activity of a second-line tuberculosis regimen 94%
- The repurposed STAT3 inhibitor pyrimethamine controls mycobacterial infection-induced vascular permeability and mycobacterial burden 90%
- Synergistic Effect of Thermoneutral Housing and Chronotherapeutic PD-1 Blockade Overcomes Melanoma Resistance 88%
Similar papers in this journal
- Dual human lung models reveal compartment-specific activity of anti-tuberculosis drugs and host-directed therapies 92%
- Natural products lysobactin and sorangicin A show in vitro activity against Mycobacterium abscessus complex 92%
- Genetic determinants of intrinsic antibiotic tolerance in Mycobacterium avium 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.